NasdaqGS - Nasdaq Real Time Price
USD
Genmab A/S (GMAB)
26.02
-0.10
(-0.38%)
At close: June 29 at 4:00:01 PM EDT
26.61
+0.59
(+2.27%)
After hours: June 29 at 6:58:09 PM EDT
Trade GMAB on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for GMAB
Chart does not reflect overnight price.
- Previous Close
26.12 - Open
26.23 - Bid 18.88 x 200
- Ask 33.58 x 200
- Day's Range
25.97 - 26.42 - 52 Week Range
20.23 - 35.43 - Volume
2,017,264 - Avg. Volume
1,794,452 - Market Cap (intraday)
15.975B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
19.86 - EPS (TTM)
1.31 - Earnings Date (est.) Aug 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.82
Recent News
View More
Performance Overview
Trailing total returns as of 6/29/2026, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
GMAB
17.37%
OMX Copenhagen 25 Index (^OMXC25)
1.04%
1-Year Return
GMAB
26.93%
OMX Copenhagen 25 Index (^OMXC25)
4.76%
3-Year Return
GMAB
30.52%
OMX Copenhagen 25 Index (^OMXC25)
0.73%
5-Year Return
GMAB
37.24%
OMX Copenhagen 25 Index (^OMXC25)
3.40%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/26/2026
-
Market Cap
15.88B
-
Enterprise Value
19.71B
-
Trailing P/E
19.86
-
Forward P/E
15.58
-
PEG Ratio (5yr expected)
1.76
-
Price/Sales (ttm)
4.20
-
Price/Book (mrq)
2.82
-
Enterprise Value/Revenue
5.05
-
Enterprise Value/EBITDA
15.33
Financial Highlights
Profitability and Income Statement
-
Profit Margin
21.05%
-
Return on Assets (ttm)
8.48%
-
Return on Equity (ttm)
14.96%
-
Revenue (ttm)
3.9B
-
Net Income Avi to Common (ttm)
821M
-
Diluted EPS (ttm)
1.31
Balance Sheet and Cash Flow
-
Total Cash (mrq)
1.52B
-
Total Debt/Equity (mrq)
94.18%
-
Levered Free Cash Flow (ttm)
830.37M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, recent rally in China markets could be a dead cat bounce or it could not; Sigma finds a moat in Chemist Warehouse; tapping the brakes as EV demand grows in China; Genmab, Teva Pharmaceutical Industries, and Macy’s. .
-
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Zalando poised as a winner; growth looms for Scotts Miracle Gro; how does Buffett defend Berkshire's cash hoard now; and Bio-Rad, Genmab A/S, and Topsports International.
-
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, European interest-rate cuts on the horizon; firm opportunities among drug and biopharma firms; and reports Tesla's affordable vehicle will be canceled; and Lazard, PVH, and Genmab.
